JW Holdings Reports Q1 2026 Operating Profit Surge 98.2% YoY, Sales Up 8.1%
-
Preliminary Q1 2026 consolidated results: Sales 198.5 billion won (+8.1% YoY, +1.6% QoQ)
-
Operating profit 31.7 billion won (+40.4% YoY, +98.2% QoQ)
-
Net income 28.5 billion won (+62.3% YoY, +89.0% QoQ)
-
Pre-tax profit 35.8 billion won (+56.9% YoY, +106.7% QoQ)
-
Figures are preliminary and subject to change after external audit review
KOSPI Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: JW Pharmaceutical (001060)
-
Submission: JW Pharmaceutical
-
Receipt: 05-12-2026
-
Under KRX KOSPI Market Division